Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

NIAID Data Ecosystem2026-03-13 收录

KRAS突变癌症治疗

I期临床试验安全性

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2379791 数据链接链接失效反馈

官方服务：

资源简介：

This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied.

创建时间：

2022-03-15

Supplementary table 1.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies

肿瘤药物研发

I期临床试验安全性

Supplementary Figure 1. Dose linearity and proportionality in plasma following multiple doses of talazoparib. Supplementary material. Medical history of the patient in Co

DataCite Commons2024-05-17 更新70

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

KRAS突变癌症治疗

Panitumumab疗效评估

The goal of this clinical research study is to learn if panitumumab can help to control advanced cancer of the small bowel or ampulla of Vater. The safety of this drug will also be studied.

NIAID Data Ecosystem40

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5‑Fluoro-4-(3H)‑quinazolinone Aryl Urea pan-RAF Kinase Inhibitor

KRAS突变癌症治疗

激酶抑制剂开发

Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (7), which features a fluoroquinazolinone hinge-binding motif. By minimizing relian

Figshare2021-03-29 更新20

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

KRAS突变癌症治疗

药物组合耐药机制

There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeuti

NIAID Data Ecosystem60

Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers

SHP2变构抑制剂发现

KRAS突变癌症治疗

Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) is a highly attractive therapeutic target for treating Kirsten rat sarcoma viral oncogene (KRAS) mutant cancers. In this work, a

NIAID Data Ecosystem40

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

资源简介：

相关数据集